Bank of America
DAWN

Bank of America’s Day One Biopharmaceuticals DAWN Stock Holding History

Bank of America’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,000
Closed -$138K – 8211
2024
Q2 		$138K Hold
10,000
– – ﹤0.01% 6083
2024
Q1 		$165K Buy
+10,000
New +$150K ﹤0.01% 5984

Other funds holding DAWN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 26.7% 1-Year Est. Return

Bank of America's DAWN Position: Q1 2026 in Review

Bank of America increased its Day One Biopharmaceuticals (DAWN) stake by 76% in Q1 2026, buying an estimated $11.5M and bringing the position to 1,902,868 shares worth $40.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1748.

Bank of America first reported a position in DAWN in Q2 2021 and has held it in 20 quarters since. 207 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Bank of America held 1,902,868 shares of Day One Biopharmaceuticals worth $40.8M as of Q1 2026.
  • Bank of America bought 819,050 Day One Biopharmaceuticals shares in Q1 2026, an estimated $11.5M.
  • Day One Biopharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #1748 holding.
  • Bank of America first reported a position in Day One Biopharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • 207 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.